Published on: October 2026
MUCOADHESIVE OCULAR INSERTS FOR THE TREATMENT OF FUNGAL KERATITIS: BIOPOLYMER ENGINEERING AND UNIDIRECTIONAL DRUG DELIVERY STRATEGIES
Karishma Nishad
Deepak Kumar Singh
Article Status
Available Documents
Abstract
Objective: This review examines whether biopolymer-based mucoadhesive ocular inserts, particularly those engineered for unidirectional (cornea-facing) release, can overcome the precorneal and corneal barriers that limit topical antifungal therapy, using fluconazole as the model drug.
Methods: Literature on ocular barriers, fungal keratitis, fluconazole, ocular inserts, mucoadhesive biopolymers, directional release, formulation, characterization and preclinical evaluation was surveyed from PubMed, ScienceDirect, Scopus and Google Scholar and synthesized into comparative tables.
Key Findings: Chitosan, alginate, hyaluronic acid and cellulose derivatives provide the hydration, chain mobility and functional groups needed for adhesion to the ocular mucin layer, and chitosan adds antimicrobial and permeation-enhancing effects. Fluconazole-loaded nanoparticles, niosomes, nanogels, in situ gels and freeze-dried chitosan inserts have improved corneal permeation, retention and aqueous humour exposure in animal models. Drug-impermeable backing layers, borrowed from buccal patches, can steer release toward the cornea, although ocular evidence remains limited.
Conclusion: Mucoadhesive, unidirectional ocular inserts are a rational platform for fluconazole delivery in yeast keratitis. Their clinical future depends on reproducible directional release, patient comfort, validated sterilization and well-designed clinical studies.
Keywords: Fungal keratitis; Fluconazole; Ocular insert; Mucoadhesion; Chitosan; Biopolymers; Unidirectional release; Backing layer; Corneal permeation
How to Cite this Paper
Nishad, K. (2026). Mucoadhesive Ocular Inserts for the Treatment of Fungal Keratitis: Biopolymer Engineering and Unidirectional Drug Delivery Strategies. International Journal of Creative and Open Research in Engineering and Management, <i>02</i>(10), 1-9. https://doi.org/10.55041/ijcope.v2i10.125
Nishad, Karishma. "Mucoadhesive Ocular Inserts for the Treatment of Fungal Keratitis: Biopolymer Engineering and Unidirectional Drug Delivery Strategies." International Journal of Creative and Open Research in Engineering and Management, vol. 02, no. 10, 2026, pp. 1-9. doi:https://doi.org/10.55041/ijcope.v2i10.125.
Nishad, Karishma. "Mucoadhesive Ocular Inserts for the Treatment of Fungal Keratitis: Biopolymer Engineering and Unidirectional Drug Delivery Strategies." International Journal of Creative and Open Research in Engineering and Management 02, no. 10 (2026): 1-9. https://doi.org/https://doi.org/10.55041/ijcope.v2i10.125.
References
[1] Abdelmonem R, El-Nabarawi MA, Attia AM, Teaima M. Ocular delivery of natamycin solid lipid nanoparticle loaded mucoadhesive gel: formulation, characterization and in vivo study. Int J Appl Pharm. 2020;12(5):173–180.[2] Abou El Ela AESF, Ibrahim MA, Alqahtani Y, Almomen A, Aleanizy FS. Fluconazole nanoparticles prepared by antisolvent precipitation technique: physicochemical, in vitro, ex vivo and in vivo ocular evaluation. Saudi Pharm J. 2021;29(6):576–585.
[3] Aburahma MH, Mahmoud AA. Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: preparation and in vitro/in vivo evaluation. AAPS PharmSciTech. 2011;12(4):1335–1347.
[4] Bernkop-Schnürch A, Dünnhaupt S. Chitosan-based drug delivery systems. Eur J Pharm Biopharm. 2012;81(3):463–469.
[5] Brown L, Leck AK, Gichangi M, Burton MJ, Denning DW. The global incidence and diagnosis of fungal keratitis. Lancet Infect Dis. 2021;21(3):e49–e57.
[6] Debruyne D, Ryckelynck JP. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet. 1993;24(1):10–27.
[7] DelMonte DW, Kim T. Anatomy and physiology of the cornea. J Cataract Refract Surg. 2011;37(3):588–598.
[8] Elmotasem H, Awad GEA. A stepwise optimization strategy to formulate in situ gelling formulations comprising fluconazole-hydroxypropyl-beta-cyclodextrin complex loaded niosomal vesicles and Eudragit nanoparticles for enhanced antifungal activity and prolonged ocular delivery. Asian J Pharm Sci. 2020;15(5):617–636.
[9] Felt O, Furrer P, Mayer JM, Plazonnet B, Buri P, Gurny R. Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention. Int J Pharm. 1999;180(2):185–193.
[10] Fetih G. Fluconazole-loaded niosomal gels as a topical ocular drug delivery system for corneal fungal infections. J Drug Deliv Sci Technol. 2016;35. doi:10.1016/j.jddst.2016.06.002.
Ethical Compliance & Review Process
- •All submissions are screened under plagiarism detection.
- •Review follows editorial policy.
- •Authors retain copyright.
- •Peer Review Type: Double-Blind Peer Review
- •Published on: Oct 24 2026
This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. You are free to share and adapt this work for non-commercial purposes with proper attribution.

